Strong balance sheet$12.66 million of cash reserves as @ 31 December 2019
With US approval revenue will triple (currently at 14 million)Cyclopharm is a radiopharmaceutical company primarily involved in the field of nuclear medicine. It operates in the diagnostic imaging field, specialising in lung health.
The company’s core radiopharmaceutical product is Technegas, a structured ultra-fine dispersion of radioactive labelled carbon used in lung ventilation imaging.
Cyclopharm has a global presence, distributing its products in 57 countries throughout the world with more than 1,500 medicine departments utilising Technegas.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.005(0.50%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | $1.00 | $215.2K | 211.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10089 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 3762 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |